Artificial intelligence company Anthropic has officially released Claude Fable 5, the public-facing version of its previously restricted Claude Mythos model, marking a major development in the company’s frontier AI lineup.
Claude Mythos had earlier been withheld from public release due to internal safety concerns, with engineers warning that its advanced capabilities in areas such as cybersecurity and complex reasoning could pose significant misuse risks.
The newly released Claude Fable 5 retains much of Mythos’ underlying architecture but introduces extensive safety guardrails designed to prevent harmful applications. According to the company, the system now restricts or blocks high-risk queries related to cybersecurity, biology, and other sensitive domains, automatically routing some requests to earlier, less capable models when necessary.
Anthropic says the goal is to strike a balance between advanced AI capability and controlled deployment, allowing broader access while reducing the risk of misuse.
Related
- Anthropic Unveils Mythos AI Model in New Cybersecurity Push
- Claude AI vs ChatGPT: Enterprise And Safety Comparison
- Anthropic’s Survey of 80,000 Claude Users Reveals Daily AI Usage
- Meta Delays New AI Model Release Over Performance Concerns
The model is being rolled out across cloud platforms and enterprise tools, with phased availability expected for different user tiers in the coming weeks. Early benchmarks suggest improved performance in long-context reasoning, coding, and agent-based workflows compared to previous Claude models.
The release comes amid ongoing global debate over how frontier AI systems should be governed, particularly those previously deemed too powerful for unrestricted public use.
Experts say the move reflects a growing industry trend: instead of withholding advanced models entirely, companies are increasingly opting to release “safeguarded versions” with embedded limitations.
Anthropic has not ruled out expanding access to the full Mythos-level system in the future, but says any such decision would depend on further safety validation and controlled testing.
